RNA Target for Cancer and Neurodegenerative Diseases (G106480435)

Target Name: RNU6-61P

NCBI ID: G106480435

RNU6-61P

Other Name(s): RNU6-61 | RNA, U6 small nuclear 61, pseudogene

RNA Target for Cancer and Neurodegenerative Diseases

RNU6-61P, also known as human repetitive nuclear unit 6 (Rnu6), is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

RNA molecules are an essential part of the human body, serving as the blueprints for the development and maintenance of all living organisms. RNU6-61P is a small non-coding RNA molecule that is expressed in almost all human tissues and is involved in the regulation of various cellular processes, including cell growth, differentiation, and RNA translation.

One of the key features of RNU6-61P is its ability to interact with other molecules in the cell. It has been shown to play a role in the regulation of gene expression by binding to specific DNA sequences and affecting the activity of transcription factors, such as RNA polymerase II.

In addition to its role in gene regulation, RNU6-61P has also been shown to play a key role in the development and progression of various diseases. For example, studies have shown that high levels of RNU6-61P are associated with the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Furthermore, RNU6-61P has also been shown to be involved in the regulation of immune responses, which is critical for maintaining the health and function of the immune system.

The potential drug target and biomarker properties of RNU6-61P make it an attractive target for researchers to study and develop new treatments for various diseases. By targeting the regulation of gene expression and immune responses, researchers may be able to develop new treatments for diseases such as cancer, neurodegenerative diseases, and autoimmune disorders.

In conclusion, RNU6-61P is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases. Further research is needed to understand its role in the regulation of gene expression and immune responses, and to develop new treatments for diseases.

Protein Name: RNA, U6 Small Nuclear 61, Pseudogene

The "RNU6-61P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNU6-61P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets